

GREENLEAF HEALTH

COMPLETE CAPABILITIES

OUR EXPERIENCE.
YOUR SUCCESS.

Greenleaf Health is a leading FDA regulatory consulting firm guiding companies through the changing FDA landscape.

ABOUT GREENLEAF HEALTH

250+ YEARS
OF COMBINED FDA EXPERIENCE



WHY GREENLEAF

Founded in 2007, Greenleaf Health is a leading FDA regulatory consulting firm that provides strategic and technical guidance to pharmaceutical, biotechnology, and medical device companies researching, developing, and manufacturing innovative solutions to pressing global public health challenges.

Greenleaf's robust blend of technical skill and FDA institutional knowledge enables the firm to provide reliable, objective guidance to companies developing medical products for the U.S. market.

UNMATCHED EXPERTISE

Greenleaf's team brings unmatched expertise that companies need when navigating today's evolving FDA regulatory environment. The firm includes former leaders and regulatory professionals from the FDA, Capitol Hill, top global pharmaceutical and medical device companies, leading law firms, and the U.S. biotechnology trade organization.

Greenleaf experts draw on a combined total of more than 250 years of FDA experience and a network of technical specialists. This wealth of experience informs Greenleaf's understanding of the broad life sciences industry and allows us to deliver valuable insight throughout the product lifecycle.

COMPREHENSIVE SERVICES



PRODUCT QUALITY, MANUFACTURING & COMPLIANCE

Greenleaf experts identify and promote practices and procedures that will align a client's approach with the FDA's quality, safety, and compliance expectations.



COMPLIANCE AUDIT, TRAINING & REMEDIATION

Greenleaf works with a network of independent technical experts who provide comprehensive on-site compliance assessments, remediation, and inspection readiness.



DRUG & BIOLOGICAL PRODUCTS

Greenleaf serves as a trusted regulatory partner, advising companies on the complex process of bringing new therapeutics to market in today's evolving FDA environment.



MEDICAL DEVICE & COMBINATION PRODUCTS

Greenleaf applies extensive regulatory expertise to guide medical device clients from early-stage development to marketing authorization and throughout the product lifecycle.



CELL & GENE THERAPY

Greenleaf assists sponsors of cell and gene therapies by optimizing FDA interactions and submissions to support development, manufacturing, quality, and regulatory review.



REAL-WORLD EVIDENCE (RWE)

Greenleaf Health and Trio Health have united to provide a cutting-edge combination of technology and regulatory insight via Trio's groundbreaking real-world evidence technology platform.



ADVISORY SERVICES

Greenleaf understands the complex environment within which life sciences transactions take place and performs in-depth regulatory risk assessments tailored to investors' needs.



LITIGATION SUPPORT

Greenleaf works closely with litigators representing FDA-regulated clients in a wide array of disputes related to medical devices and product quality, manufacturing, and compliance.



GREENLEAF TEAMS

DRUG & BIOLOGICAL PRODUCTS TEAM

Greenleaf's Drug and Biological Products Team has a robust blend of regulatory and policy expertise and FDA institutional knowledge. The team's approach is guided by decades of regulatory experience in drug and biological product development, spanning all therapeutic areas.




JOHN JENKINS, M.D.
Principal, Drug & Biological Products

Former Director of the Office of New Drugs within the FDA's Center for Drug Evaluation and Research (CDER).



BOB MEYER, M.D.
Principal, Drug & Biological Products

A leader in drug and biological product lifecycle management with over 25 years of regulatory and academic leadership.



KAREN MIDTHUN, M.D.
Principal, Drug & Biological Products

An infectious disease physician by training, with a 28-year career in public service, including as Director of the FDA's Center for Biologics Evaluation and Research (CBER).



JOSEPH GRIFFIN
Executive Vice President, Drug & Biological Products

20+ years of FDA service with a vast institutional knowledge of the drug regulatory process and prescription drug promotion and labeling.



KATE COOK
Executive Vice President, Drug & Biological Products

Two decades of experience in policy development and as legal counsel on biological, medical device, and drug issues.




STEPHEN MASON
Senior Vice President, Regulatory Policy

Accomplished and diverse career specializing in regulatory and legislative policy development and analysis.



BRIAN CORRIGAN
Senior Vice President, Regulatory Policy

More than a decade of experience in the biopharmaceutical industry provides in-depth understanding of the U.S. health care system.



KATIE MCCARTHY
Senior Vice President, Regulatory Policy

10+ years of policy experience specializing in scientific and regulatory issues impacting drug and biotechnology companies.



DRUG & BIOLOGICAL PRODUCTS SERVICES

Greenleaf's Drug and Biological Products Team specializes in providing strategic and technical guidance on medical product development, regulatory review, and postmarket requirements, working closely with clients to navigate today's evolving FDA regulatory environment.



UNMATCHED REGULATORY EXPERIENCE

Greenleaf serves as a trusted regulatory partner, advising clients on the complex process of bringing new therapies to market. The team's multidisciplinary expertise helps companies evaluating and prioritizing their drug development pipeline to understand and effectively manage regulatory risk.



PREMARKET REVIEW PROCESS

Greenleaf's team of experts provides strategic and technical consultation on: scientific and regulatory practices for clinical programs and regulatory submissions; identification of and eligibility for special designations, such as breakthrough therapy designation, RMAT, fast track, and accelerated approval; and preparation for FDA milestone meetings, such as EOP2, pre-filing meetings, mid-cycle review, and end-of-review meetings.



CELL & GENE THERAPY

The Drug and Biological Products Team assists sponsors of cell and gene therapies with FDA interactions and submissions — including early INTERACT and pre-IND meetings; requests for orphan drug, RMAT, and rare pediatric disease designations; and data comparability questions — and helps to clarify FDA requirements for specific types of cellular products. The team also provides guidance on how to maximize clinical trial design for cell and gene therapies to treat rare and ultra-rare diseases.



REAL-WORLD EVIDENCE (RWE)

Greenleaf's exclusive agreement with Trio Health, a leading provider of real-time data on real-world patients, gives clients the advantage of Trio's groundbreaking Multi-Disease Platform (MDX) integrated with Greenleaf's unrivaled regulatory knowledge. Greenleaf's team of experts provides end-to-end guidance to companies utilizing MDX data on how to optimize and validate the information to drive effective regulatory strategies.

DRUG & BIOLOGICAL PRODUCT PIPELINE REVIEW SERVICES

Greenleaf works with companies to identify valuable portfolio opportunities and to understand and effectively manage regulatory risks. By assessing regulatory risk early in the drug development process, companies can allocate resources more efficiently and plan their development strategy with greater confidence.

The expansive knowledge and diverse perspectives of the collective Greenleaf team enable clients to make timely, informed decisions to optimize and strategically manage their pipelines.

The Drug and Biological Products Team helps reduce regulatory uncertainties by providing the following services:



PIPELINE REVIEW

Greenleaf experts evaluate the various components critical to a drug development pipeline's clinical and regulatory success. The team's assessments span the drug development continuum from preclinical and clinical milestones through postapproval considerations. With experience across a wide range of therapeutic areas and therapeutic modalities, Greenleaf is able to provide guidance on a variety of clinical indications and drug development issues.



GAP ANALYSIS

Greenleaf's team helps guide drug development programs forward by working with the client's technical experts to perform a systematic review of factors that may impact the success of a product. Our experts then evaluate the collected data and information, identify missing elements, and help the client develop a plan to prioritize and address programmatic needs for individual therapeutic candidates and across the portfolio. Early identification of gaps allows companies to address issues proactively and make informed decisions about a program's viability, timing, and resources.



STRATEGY DEVELOPMENT

Greenleaf works with companies to create customized drug development strategies, from early-phase to late-stage development. Greenleaf's advisors provide realistic direction by determining the strengths and weaknesses of the pipeline, highlighting potential catalysts that could impact product development, assessing the competitive landscape, and considering study concept and clinical development plan design alternatives. The result is an actionable strategy that identifies development options and meaningful benchmarks to measure success and optimizes factors such as clinical positioning, product differentiation, and regulatory approval.

PRODUCT QUALITY, MANUFACTURING & COMPLIANCE TEAM

Greenleaf's Product Quality, Manufacturing, and Compliance Team has a proven track record of achieving success and providing services that are recognized as best in class by companies seeking to strengthen their quality management systems.

To further enhance the firm's robust compliance services, Greenleaf has developed an Independent Contractor (IC) Network of additional technical experts who can be deployed to provide on-site services at entities that manufacture FDA-regulated products.



JOHN TAYLOR

**President
Principal, Compliance & Regulatory
Affairs**

Former FDA senior official held many high-profile positions at the Agency, as well as senior leadership roles within industry.



DAVID ELDER

**Executive Vice President,
Regulatory Compliance**

23-year veteran of the FDA with prominent roles in domestic and foreign inspections, recalls and emergencies, and compliance actions.



KRISTEN GRUMET

**Senior Vice President,
Regulatory Compliance**

25-year compliance career, including role as an FDA field investigator specializing in medical devices.



BRITTANY MILBY

**Executive Director of Operations,
Regulatory Compliance**

Spearheads multiple operations, including the organization and management of the Greenleaf Independent Contractor Network.



CYNTHIA SCHNEDAR

**Executive Vice President,
Regulatory Compliance**

25-year compliance career, including serving as director of the FDA's drug compliance office.



KALAH AUCHINCLOSS

**Senior Vice President, Regulatory
Compliance
Deputy General Counsel**

10+ years of experience on Capitol Hill, in the private sector, and at the FDA, including role as Deputy Chief of Staff.



LIZ OESTREICH

**Vice President,
Regulatory Compliance**

Diverse background and knowledge of legal, public policy, and non-profit sectors.



MADELEINE GIAQUINTO

Manager, Regulatory Affairs

Legal and policy expertise and experience advising on compliance with federal health programs and regulations.

ADDITIONAL TEAM MEMBERS: Laura Bartee





QUALITY & COMPLIANCE SERVICES

Greenleaf offers an enhanced portfolio of services that includes comprehensive on-site compliance assessments, remediation, and inspection readiness, in addition to the firm's core regulatory consulting capabilities.



COMPLIANCE ASSESSMENTS

Greenleaf works with life science entities to evaluate and strengthen compliance functions with an eye toward optimizing processes, mitigating risks, and creating a culture of compliance, while continuing to meet business objectives.



FDA COMMUNICATIONS

Greenleaf's best-in-class experts bring value to any communication with the FDA, including formal regulatory communication, in-person meetings, and responses to compliance actions and regulatory correspondence.



COMPLIANCE REMEDIATION

Greenleaf experts bring an unmatched level of credibility and trust when interacting with the FDA. The team has the experience and insight to successfully guide companies along the remediation pathway.



CONSULTATION, TRAINING & REGULATORY GUIDANCE

Greenleaf delivers insight and guidance that help clients achieve business and regulatory objectives. The team also develops and delivers training on a variety of regulatory subjects.




INSPECTION READINESS

Greenleaf experts strengthen clients' readiness for FDA preapproval and surveillance inspections through consulting, training, audits, and mock inspections.



GCP SERVICES

Greenleaf specialists use a risk-based methodology to develop and improve clinical quality systems. Because there is no one-size-fits-all approach to GCP compliance, each solution is built to fit the targeted needs of the client.



SUPPLY CHAIN OPTIMIZATION

Greenleaf uses a systemic approach to help clients strengthen and safeguard the integrity of their supply chain management practices and comply with the regulatory requirements of the Drug Supply Chain Security Act.



CELL & GENE THERAPY

Greenleaf helps sponsors establish manufacturing and quality controls and engage with the FDA to address potential technical and regulatory challenges related to emerging manufacturing technologies.



GOOD CLINICAL PRACTICE (GCP) SERVICES

Greenleaf's team of highly experienced specialists uses a risk-based methodology to develop and improve clinical quality systems. Because there is no one-size-fits-all approach to GCP compliance, each solution is built to fit the targeted needs of the client. The Product Quality, Manufacturing, and Compliance Team provides clinical quality and GCP services in the following areas:



COMPLIANCE ASSESSMENTS

Greenleaf works with life science entities to evaluate and strengthen clinical quality systems with an eye toward optimizing processes, mitigating risks, and creating a culture of compliance, while continuing to meet business objectives.




COMPLIANCE REMEDIATION

Greenleaf experts bring an unmatched level of credibility and trust when interacting with the FDA. The team has the experience and insight to successfully guide companies along the remediation pathway.



CONSULTATION, TRAINING & REGULATORY GUIDANCE

Greenleaf delivers insight and guidance that help clients achieve business and regulatory objectives. The team also develops and delivers training on a variety of regulatory subjects.



FDA COMMUNICATIONS

Greenleaf's best-in-class experts bring value to any communication with the FDA, including formal regulatory communications, in-person meetings, and responses to compliance actions and regulatory correspondence.



AUDITING SERVICES

Greenleaf's skilled professionals provide auditing services that include the review and audit of GCP documents, sponsor and laboratory sites, and vendors for areas of nonconformance.




INSPECTION READINESS

Greenleaf experts strengthen clients' readiness for FDA preapproval and surveillance inspections through consulting, training, audits, and mock inspections.



SUPPLY CHAIN MANAGEMENT SERVICES

Guided by decades of regulatory experience, Greenleaf consultants use a systemic approach to help clients strengthen and safeguard the integrity of their supply chain management practices and comply with the regulatory requirements of the Drug Supply Chain Security Act.



GOOD SUPPLY PRACTICES

Greenleaf works with life science entities to evaluate and strengthen good supply practices using a systemic approach to optimizing processes, mitigating risks, and creating a culture of compliance, while continuing to meet business objectives.



RESPONSIVE SERVICES

Greenleaf experts bring an unmatched level of credibility and trust when interacting with the FDA. The team has the experience and insight to successfully guide companies facing compliance issues and addressing potential and actual supply chain breaches.



AUDITING SERVICES

Greenleaf's skilled professionals provide auditing services that include the review and audit of good manufacturing, good distribution, good import/export, and product security practices.



INSPECTION READINESS

Greenleaf experts strengthen clients' readiness for FDA preapproval and surveillance inspections through consulting, training, audits, and mock inspections.



REGULATORY GUIDANCE

Greenleaf delivers insight and guidance that help companies strengthen their supply chains and comply with regulatory requirements included in the Drug Supply Chain Security Act.

MEDICAL DEVICE & COMBINATION PRODUCTS TEAM

Guided by decades of experience, Greenleaf's Medical Device and Combination Products Team provides unmatched knowledge of the life sciences regulatory process and serves as a trusted partner for companies navigating the complexities of product lifecycle management.



DANIEL SCHULTZ, M.D.
**Principal, Medical Device
& Combination Products**

Former Director of the FDA's Center for Devices and Radiological Health (CDRH); distinguished 35-year career includes service as a physician, senior FDA official, and member of the U.S. Public Health Service (USPHS).



HEATHER ROSECRANS
**Executive Vice President, Medical
Device & Combination Products**

One of the nation's leading 510(k) experts, with an FDA career that spanned more than 30 years and included a pivotal role in developing the FDA's 510(k) program.



MAURA NORDEN
**Senior Vice President, Medical Device
& Combination Products
General Counsel**

More than a decade of professional experience advising leading medical device and drug companies on a broad range of FDA regulatory matters.



KATE COOK
**Executive Vice President,
Drug & Biological Products**

Two decades of experience in policy development and as legal counsel on biological, medical device, and drug issues.



SAMANTHA EAKES
Director, Regulatory Affairs

Master's in Public Health from the Boston University School of Public Health provides critical public health, advocacy, and regulatory knowledge.



CATHERINE ROWE
**Director of Operations, Medical
Device & Combination Products**

More than 20 years of professional experience in marketing, sales, and project management.




MEDICAL DEVICE & COMBINATION PRODUCTS SERVICES

Greenleaf's Medical Device and Combination Products Team applies extensive FDA experience to determine the best regulatory approach for a product and develop a comprehensive strategy to achieve a successful result.



UNMATCHED REGULATORY EXPERIENCE

Greenleaf guides clients through the complex regulatory process, from the earliest stages of product development, through the FDA review process, to marketing authorization and compliance with postmarket requirements and quality systems.



PREMARKET REVIEW PROCESS

Greenleaf provides expert direction on scientific and regulatory strategies for clinical programs and regulatory submissions. Experts also provide recommendations and preparation for FDA meetings, including medical device advisory panel meetings, and FDA communications.



MARKETING & PROMOTIONAL PRACTICES

Greenleaf provides strategic guidance to medical device firms on labeling requirements, promotional materials, direct-to-consumer advertising review processes, and use of social media. Experts also guide companies in remediation of untitled and warning letters.



LITIGATION SUPPORT

Greenleaf's deep bench of experts can offer litigators a high-level institutional knowledge of the FDA as well as more granular expertise regarding FDA regulation of a variety of product types across the product lifecycle. Greenleaf professionals have experience preparing expert declarations, drafting professional expert reports and depositions, and testifying at trial, and have worked with litigators representing FDA-regulated clients in a wide array of disputes involving complex FDA issues.

LITIGATION SUPPORT SERVICES



In legal actions involving FDA-regulated entities, complex FDA regulatory issues are often critical components of disputes.

Greenleaf's deep bench of experienced and knowledgeable FDA experts can advise litigators grappling with FDA regulatory issues and provide authoritative, objective expert opinions that may make a difference in how disputes are resolved.

Greenleaf works closely with litigators representing FDA-regulated clients in a wide array of disputes related to medical devices and product quality, manufacturing, and compliance.



EXTENSIVE KNOWLEDGE

Greenleaf's team of experts can offer litigators a high-level institutional knowledge of the FDA as well as more granular expertise regarding FDA regulation of a variety of product types across the product lifecycle. Greenleaf's well-regarded professionals have spent decades working at the FDA in senior positions, allowing them to render thoughtful advice and authoritative opinions.



TARGETED EXPERTISE

Greenleaf has extensive, in-depth expertise regarding medical device product development and the premarket review process, as well as manufacturing, product quality and safety, compliance, and enforcement of all FDA-regulated products. Our experts have the knowledge, qualifications, and experience required to explain and clarify these and other issues to our clients, the courts, or juries and are credible, persuasive expert witnesses.



COMPREHENSIVE SERVICES

Greenleaf's experts have experience preparing expert declarations, drafting professional expert reports and depositions, and testifying at trial. Greenleaf's team has worked with litigators engaged in a variety of disputes, including complex commercial litigation, unfair competition and false advertising cases, intellectual property litigation, product liability class actions, and securities class actions.

CELL & GENE THERAPY TEAM

Experts from Greenleaf's Cell and Gene Therapy Team demonstrate unmatched levels of skill in their specialties of drug and biological products and product quality, manufacturing, and compliance. Led by Karen Midthun, M.D., and John Taylor, the team is guided by decades of regulatory experience in senior FDA positions, global public health organizations, academia, and industry.



KAREN MIDTHUN, M.D.
Principal, Drug & Biological Products

An infectious disease physician by training, with a 28-year career in public service, including as Director of the FDA's Center for Biologics.



JOHN JENKINS, M.D.
Principal, Drug & Biological Products

Former Director of the Office of New Drugs within the FDA's Center for Drugs.



BOB MEYER, M.D.
Principal, Drug & Biological Products

A leader in drug and biological product lifecycle management with over 25 years of regulatory and academic leadership.



KATE COOK
**Executive Vice President,
Drug & Biological Products**

Two decades of experience in policy development and as legal counsel on biological, medical device, and drug issues.



JOHN TAYLOR
**President
Principal, Compliance & Regulatory Affairs**

Former FDA senior official held many high-profile positions at the Agency, as well as senior leadership roles within industry.



CYNTHIA SCHNEDAR
**Executive Vice President,
Regulatory Compliance**

25-year compliance career, including serving as director of the FDA's drug compliance office.



DAVID ELDER
**Executive Vice President,
Regulatory Compliance**

23-year veteran of the FDA with prominent roles in domestic and foreign inspections, recalls and emergencies, and compliance actions.



KALAH AUCHINCLOSS
**Senior Vice President,
Regulatory Compliance**


10+ years of experience on Capitol Hill, in the private sector, and at the FDA, including role as Deputy Chief of Staff.



CELL & GENE THERAPY SERVICES



Greenleaf's cell and gene therapy services support companies striving to introduce new products to patients. The firm's team of experts has a robust blend of technical skill and FDA institutional knowledge that spans all therapeutic areas and quality, manufacturing, and compliance systems. By working cross-functionally, Greenleaf ensures that clients have the comprehensive, specialized guidance needed to understand and navigate the complex regulatory landscape for cell and gene therapies.



PRODUCT DEVELOPMENT & REVIEW

Greenleaf's team specializes in strategic communications with the FDA at every stage of product development – early INTERACT meetings, pre-IND and meetings throughout development, correspondence, clinical trial design, submissions, FDA review communications and labeling discussions, and postmarket requirements.



MANUFACTURING & QUALITY CONTROLS

Greenleaf experts provide strategic and technical support for establishing manufacturing and quality controls; pre- and postapproval inspection readiness; compliance assessments; evaluating and responding to FDA regulatory correspondence; and engaging with CBER's Advanced Technologies Team.




REGULATORY LANDSCAPE

Greenleaf experts monitor and analyze the regulatory environment for emerging trends in cell and gene therapy regulation – including orphan drug designation and exclusivity, long-term follow-up requirements, companion diagnostics, the development and use of real-world evidence, and other agency policies and actions that could potentially impact current development programs – as well as changes to the competitive landscape for cell and gene therapies.

REAL-WORLD EVIDENCE TEAM

Greenleaf's team of regulatory experts provides unmatched insight and consultation on all aspects of the FDA's regulatory application of real-world evidence (RWE).

The combined achievements and substantial qualifications of the full Greenleaf team enable a cross-functional, full-service engagement that ensures clients can count on expert direction as they encounter complex regulatory challenges.



JOHN JENKINS, M.D.
Principal, Drug & Biological Products

A 25-year career at the FDA, with 15 years in senior leadership positions within the Center for Drug Evaluation and Research, including as Director of the Office of New Drugs.



BOB MEYER, M.D.
Principal, Drug & Biological Products

More than 25 years of regulatory, industry, and academic leadership, including prominent roles at the FDA, Merck, and the University of Virginia.



KAREN MIDTHUN, M.D.
Principal, Drug & Biological Products

An infectious disease physician by training, with a 28-year career in public service, including as Director of the FDA's Center for Biologics Evaluation and Research.



SEAN HILSCHER
**Associate Vice President,
Regulatory Affairs**

More than 10 years of experience as a consultant and product manager in the international and U.S. health care markets.



PATRICK RONAN
Chief Executive Officer

20+ years of leadership experience that includes positions on Capitol Hill, at a leading global pharmaceutical company, and at the FDA, serving as a principal advisor to a number of FDA commissioners.



REAL-WORLD EVIDENCE SERVICES

Real-world evidence — the concept of using real-world data (RWD) to improve clinical evidence — has the potential to transform the drug development landscape.

The Food and Drug Administration recognizes the opportunities presented by RWE and is developing a new paradigm for its use in regulatory decision-making.

Companies prepared to employ the power of RWE will require more than just raw data — that's why Greenleaf has partnered with Trio Health to provide a cutting-edge combination of technology and regulatory insight.



GREENLEAF + TRIO

Greenleaf's exclusive agreement with Trio Health, a leading provider of real-time data on real-world patients, gives clients the advantage of Trio's groundbreaking Multi-Disease Platform (MDX) technology integrated with Greenleaf's unrivaled regulatory knowledge. The result is a comprehensive resource for enhancing and contextualizing evidence derived from RWD.



MDX PLATFORM

The first-of-its-kind MDX platform tracks patients throughout the course of their treatment by combining disparate information from the physician, pharmacy, and payer 'trio.' MDX offers life science customers best-in-class speed, data certainty, and unparalleled visibility across the clinical and commercial lifecycle.

Trio's comprehensive and high-quality databases are on caliber with FDA-level rigor, giving pharmaceutical and biotechnology companies, specialty pharmacies, and physicians access to information and opportunities that can be leveraged to support pre- and postmarketing activities.



UNRIVALED INSIGHT

When integrated with Greenleaf's regulatory expertise, Trio's advanced analytics MDX platform delivers unrivaled insights to the industry. Clients gain the ability to transform real-world data into actionable intelligence to innovate and make better decisions, with greater confidence, throughout the product lifecycle. Greenleaf's team of regulatory experts provides end-to-end guidance to companies utilizing MDX data on how to optimize and validate the information to drive effective regulatory strategies.



ADVISORY SERVICES TEAM

Greenleaf's team of advisors offers a rare blend of perspectives developed as leaders in both the public and private sectors. This wealth of experience informs Greenleaf's understanding of the broad life sciences industry and enables us to deliver valuable insight throughout the product lifecycle.



BRIAN CORRIGAN
SVP, Regulatory Policy

More than a decade of experience in the biopharmaceutical industry provides in-depth understanding of the U.S. health care system.



JOHN TAYLOR
**President and Principal,
Compliance & Regulatory Affairs**

Former FDA senior official held many high-profile positions at the Agency, as well as leadership roles within industry.



JOHN JENKINS, M.D.
**Principal, Drug &
Biological Products**

Former Director of the Office of New Drugs within the FDA's Center for Drug Evaluation and Research (CDER).



BOB MEYER, M.D.
Principal, Drug & Biological Products

A leader in drug and biological product lifecycle management with over 25 years of regulatory and academic leadership.



KAREN MIDTHUN, M.D.
Principal, Drug & Biological Products

28-year career in public service, including as Director of the FDA's Center for Biologics Evaluation and Research (CBER).



DANIEL SCHULTZ, M.D.
**Principal, Medical Device
& Combination Products**

35-year career includes service as Director of the FDA's Center for Devices and Radiological Health (CDRH).



KATE COOK
EVP, Drug & Biological Products

Two decades of experience in policy development and as legal counsel on biological, medical device, and drug issues.



MAURA NORDEN
**SVP, Medical Device &
Combination Products**

More than a decade of experience advising medical device and drug companies on a broad range of FDA regulatory matters.



DAVID ELDER
EVP, Regulatory Compliance

23-year veteran of the FDA with prominent roles in global inspections, emergencies, and compliance actions.



ADVISORY SERVICES

Greenleaf's in-depth knowledge and understanding of the FDA equips clients with a trusted partner when considering life sciences transactions. Greenleaf's advisory services are more than a compilation of public data. Greenleaf goes a step further by using the firm's vast institutional knowledge to provide in-depth analyses tailored to our clients' specific needs.

The firm's multidisciplinary team uses its extensive expertise to perform risk assessments that take into account business objectives, transaction timelines, and the industry landscape. The end result is an unbiased analysis identifying a target company's key regulatory risks, likelihood of the risks materializing, potential impact on the business, and opportunities to manage and mitigate risks in order to achieve desired regulatory outcomes. Greenleaf's comprehensive due diligence services evaluate a company's pipeline, or a specific asset, in the following areas:



PRODUCT DEVELOPMENT & REVIEW

Analysis of the target company's regulatory filings and product development plans, including approvals and clearances, special designations, advisory committee decisions, labeling review, and investigational products.



QUALITY MANUFACTURING

Assessment of the target company's manufacturing practices, compliance with quality system regulations (QSRs), good manufacturing practices (GMPs), and identification of inconsistencies that may affect the regulatory risk of a product or the company.



IDENTIFICATION OF REGULATORY RISK

Evaluation of the target company's compliance with FDA regulations and identification of issues that may require attention and resources for remediation.

OUR EXPERIENCE.
YOUR SUCCESS.